Past year - not a step forward, to say the least. Market cap is down to US$45.47M.
stocktranscript.com 8/29/15
>>Prana Biotechnology Limited (NASDAQ:PRAN) announced its financial results for the 12 months to June 30, 2015. Full year revenue of $176,842, down 51% on prior corresponding period (pcp); Fully year loss after tax of $5,885,069, down 56% on pcp; and Cash position at June 30, 2015, of $34.9 million.
Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders.
Prana Biotechnology Limited (NASDAQ:PRAN) shares moved down -4.29% in last trading session and ended the day at $0.89. PRAN return on assets is -58.50%. Prana Biotechnology Limited (NASDAQ:PRAN) quarterly performance is -35.03%.<<
PBT Price at posting:
13.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)